BR112017013413A2 - peptídeos antagonistas de cgrp - Google Patents

peptídeos antagonistas de cgrp

Info

Publication number
BR112017013413A2
BR112017013413A2 BR112017013413-6A BR112017013413A BR112017013413A2 BR 112017013413 A2 BR112017013413 A2 BR 112017013413A2 BR 112017013413 A BR112017013413 A BR 112017013413A BR 112017013413 A2 BR112017013413 A2 BR 112017013413A2
Authority
BR
Brazil
Prior art keywords
cgrp antagonist
antagonist peptides
compounds
formula
peptides
Prior art date
Application number
BR112017013413-6A
Other languages
English (en)
Inventor
Wisniewski Kazimierz
Jiang Guangcheng
K. Rabinovich Aleksandr
J. Sueiras-Diaz Javier
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of BR112017013413A2 publication Critical patent/BR112017013413A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)

Abstract

essa descrição refere-se a compostos de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, em que m, p, a, ar1, ar2, ar3, r1, r2 e r3 são definidos no pedido. os compostos da fórmula (i) podem ser usados como antagonistas de cgrp e podem ser usados para tratar a enxaqueca.
BR112017013413-6A 2015-01-06 2016-01-06 peptídeos antagonistas de cgrp BR112017013413A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562100371P 2015-01-06 2015-01-06
US62/100,371 2015-01-06
PCT/EP2016/050110 WO2016110499A1 (en) 2015-01-06 2016-01-06 Cgrp antagonist peptides

Publications (1)

Publication Number Publication Date
BR112017013413A2 true BR112017013413A2 (pt) 2018-01-09

Family

ID=55071041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013413-6A BR112017013413A2 (pt) 2015-01-06 2016-01-06 peptídeos antagonistas de cgrp

Country Status (34)

Country Link
US (1) US9969775B2 (pt)
EP (1) EP3242882B1 (pt)
JP (1) JP6929227B2 (pt)
KR (1) KR20170102302A (pt)
CN (1) CN107207567B (pt)
AR (1) AR103499A1 (pt)
AU (1) AU2016206059B2 (pt)
BR (1) BR112017013413A2 (pt)
CA (1) CA2973041A1 (pt)
CL (1) CL2017001761A1 (pt)
CO (1) CO2017007940A2 (pt)
DK (1) DK3242882T3 (pt)
EA (1) EA032082B1 (pt)
ES (1) ES2924410T3 (pt)
HR (1) HRP20220941T1 (pt)
HU (1) HUE059379T2 (pt)
IL (1) IL252903B (pt)
JO (1) JO3669B1 (pt)
LT (1) LT3242882T (pt)
MA (1) MA41311B1 (pt)
MD (1) MD3242882T2 (pt)
MX (1) MX2017008893A (pt)
MY (1) MY196439A (pt)
PH (1) PH12017501214A1 (pt)
PL (1) PL3242882T3 (pt)
PT (1) PT3242882T (pt)
RS (1) RS63467B1 (pt)
SA (1) SA517381865B1 (pt)
SG (1) SG11201705306UA (pt)
SI (1) SI3242882T1 (pt)
TN (1) TN2017000248A1 (pt)
TW (1) TWI717331B (pt)
UA (1) UA121490C2 (pt)
WO (1) WO2016110499A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018362018A1 (en) * 2017-11-06 2020-06-25 Auckland Uniservices Limited Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268474B1 (en) * 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CN101072771B (zh) * 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
EP1838725A1 (en) * 2005-01-17 2007-10-03 Jerini AG C5a receptor antagonists
US7994325B2 (en) * 2005-03-14 2011-08-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AP2008004467A0 (en) * 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
MX2008015906A (es) * 2006-06-13 2009-03-06 Vertex Pharma Antagonistas del receptor del peptido relacionado con el gen de calcitonina.
KR101855242B1 (ko) * 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도

Also Published As

Publication number Publication date
AR103499A1 (es) 2017-05-17
KR20170102302A (ko) 2017-09-08
MX2017008893A (es) 2017-10-25
IL252903B (en) 2021-01-31
MA41311B1 (fr) 2022-10-31
DK3242882T3 (en) 2022-08-08
LT3242882T (lt) 2022-08-25
IL252903A0 (en) 2017-08-31
EP3242882B1 (en) 2022-05-04
HUE059379T2 (hu) 2022-11-28
TN2017000248A1 (en) 2018-10-19
EA032082B1 (ru) 2019-04-30
CA2973041A1 (en) 2016-07-14
CO2017007940A2 (es) 2017-10-31
PH12017501214A1 (en) 2018-01-08
MA41311A (fr) 2017-11-14
AU2016206059B2 (en) 2019-07-25
CL2017001761A1 (es) 2018-01-26
SG11201705306UA (en) 2017-07-28
US20180002378A1 (en) 2018-01-04
AU2016206059A1 (en) 2017-07-20
WO2016110499A1 (en) 2016-07-14
CN107207567A (zh) 2017-09-26
PT3242882T (pt) 2022-08-09
HRP20220941T1 (hr) 2022-10-28
JP2018505213A (ja) 2018-02-22
SI3242882T1 (sl) 2022-09-30
ES2924410T3 (es) 2022-10-06
TW201630929A (zh) 2016-09-01
UA121490C2 (uk) 2020-06-10
US9969775B2 (en) 2018-05-15
SA517381865B1 (ar) 2021-09-15
MY196439A (en) 2023-04-11
CN107207567B (zh) 2021-11-23
JP6929227B2 (ja) 2021-09-01
JO3669B1 (ar) 2020-08-27
RS63467B1 (sr) 2022-08-31
TWI717331B (zh) 2021-02-01
PL3242882T3 (pl) 2022-10-31
EA201791456A1 (ru) 2018-01-31
MD3242882T2 (ro) 2022-10-31
EP3242882A1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
NI201900019A (es) Inhibidores de procesos metabólicos celulares
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018070549A2 (pt) degradantes de proteína mdm2
BR112018070859A2 (pt) degradantes da proteína de bet
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112017017135A2 (pt) inibidores de tgf-beta
BR112017024555A2 (pt) moduladores de ccr2
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
BR112017025781A2 (pt) derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak
CL2015002897A1 (es) Inhibidores de bace1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112018007664A2 (pt) antagonistas de ep4
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
CL2018003417A1 (es) Nuevos compuestos.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017018198A2 (pt) inibição da atividade de olig2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 513/04 , C07K 7/64 , A61K 38/12

Ipc: C07D 513/04 (2006.01), C07K 7/64 (2006.01), A61K 3